Breaking News Instant updates and real-time market news.

REGN

Regeneron

$392.25

-5.38 (-1.35%)

, SNY

Sanofi

$43.82

-0.57 (-1.28%)

08:55
09/15/18
09/15
08:55
09/15/18
08:55

Regeneron says Dupixent showed 'significant improvement' in atopic dermatitis

Regeneron Pharmaceuticals (REGN) and Sanofi (SNY) presented detailed results from a pivotal Phase 3 trial showing Dupixent monotherapy demonstrated a "significant improvement" in signs and symptoms of atopic dermatitis and certain quality of life measures in adolescent patients with moderate-to-severe atopic dermatitis, whose disease was inadequately controlled with topical therapies or for whom topical treatment was medically inadvisable. These data were presented at the 27th European Academy of Dermatology and Venereology Congress in Paris, France. The co-primary endpoint outside of the U.S. was 75% improvement in Eczema Area and Severity Index at 16 weeks. In the U.S., the primary endpoint was the proportion of patients achieving Investigator's Global Assessment score of 0 or 1.41.5% of patients who received Dupixent every two weeks and 38% of patients who received Dupixent every four weeks achieved 75% or greater skin improvement compared to 8% with placebo; 24% of patients who received weight-based dosing of Dupixent every two weeks and 18% of patients who received a fixed dose of Dupixent every four weeks achieved the primary endpoint - clear or almost-clear skin - compared with 2% with placebo. With regard to key secondary endpoints at 16 weeks, there was a 66% improvement in the Dupixent every two weeks group and 65% improvement in the Dupixent every four weeks group in average percent change from baseline in EASI score compared with a 24% improvement in the placebo group. And there was a 48% improvement in the Dupixent every two weeks group and 45.5% improvement in the Dupixent every four weeks group in average percent change from baseline in the pruritus numerical rating scale compared with a 19% improvement in the placebo group. The overall rate of adverse events was 72% for Dupixent every two weeks, 64% for Dupixent every four weeks and 69% for placebo. Adverse events that were observed more frequently with Dupixent included injection site reactions and conjunctivitis. Skin infections were numerically lower in the Dupixent groups.

REGN

Regeneron

$392.25

-5.38 (-1.35%)

SNY

Sanofi

$43.82

-0.57 (-1.28%)

  • 15

    Sep

  • 27

    Sep

  • 20

    Oct

  • 28

    Oct

  • 29

    Oct

  • 28

    Jan

  • 22

    Mar

  • 28

    Apr

  • 13

    May

REGN Regeneron
$392.25

-5.38 (-1.35%)

08/08/18
PIPR
08/08/18
NO CHANGE
PIPR
Overweight
Piper says CMS Part B headlines 'scary,' but Regeneron pullback an overreaction
Piper Jaffray analyst Christopher Raymond said he would be a buyer on weakness in shares of Regeneron after CMS announced new rules giving Medicare Advantage plans the option of implementing "step therapy" to introduce competition. He checked in with leading drug pricing and reimbursement experts, whose view is that this may drive discounting and competition between Eylea and Lucentis, much like what exists today with private pay plans. After speaking with management, Raymond estimates about 3.4% of 2019 Eylea revenue is at risk. Assuming Regeneron has to price at Eylea at a 30% discount translates to a roughly $40M revenue impact and a 36c, or 1.5%, hit to EPS in 2019, said Raymond, who called the 6% pullback in the stock an overreaction in light of those estimates. He maintains an Overweight rating on Regeneron shares.
08/13/18
PIPR
08/13/18
NO CHANGE
PIPR
Overweight
Regeneron should be bought on 'largely meaningless' CRL, says Piper Jaffray
Piper Jaffray analyst Christopher Raymond recommends buying shares of Regeneron Pharmaceuticals on weakness after the company received a Complete Response Letter from the FDA regarding Eylea's supplemental Biologics License Application for Q12W dosing in wet macular degeneration. The CRL is "largely meaningless" as this label expansion is almost entirely a defensive move by Regeneron to counter potential Q12W labeling by competitor Novartis' (NVS) RTH258, Raymond tells investors in a research note. The analyst has "reasonable confidence" that approval for this label will come within two months. He keeps an Overweight rating on shares of Regeneron.
08/16/18
PIPR
08/16/18
NO CHANGE
Target $450
PIPR
Overweight
Regeneron's fasinumab safety remains 'open question,' says Piper Jaffray
Piper Jaffray analyst Christopher Raymond backed an Overweight rating on Regeneron Pharmaceuticals (REGN) shares following this morning's release of fasinumab results, saying the drug and partner Teva's (TEVA) anti-NGF antibody met its primary and secondary efficacy pain and functional endpoints in a Phase 3 trial of patients with chronic pain from osteoarthritis of the knee or hip. Raymond says the efficacy "was never really in doubt," but the bigger focus for the drug is safety, and will wait for detailed data at an upcoming medical meeting, but notes that fasinumab's arthropathy rate appears "slightly higher" than that of tanezumab. Given the severity of the ongoing opioid epidemic and relative lack of alternatives for these patients outside of total joint replacement, the analyst thinks the appetite of regulators and potential market for new effective, non-opioid chronic pain therapies like anti-NGF clearly exists, though he will leave this as an unmodeled potential source of upside for now,
09/13/18
STFL
09/13/18
INITIATION
Target $127
STFL
Buy
AnaptysBio resumed with a Buy at Stifel
Stifel analyst Derek Archila resumed coverage of AnaptysBio (ANAB) with a Buy rating and $127 price target, stating that he is positively biased heading into etokimab's Phase 2a results for severe eosinophilic asthma, given his view on the strong rationale for the inhibition of IL-33, etokimab's meaningful reduction of eosinophils seen in an earlier Phase 2a study, and the success of Regeneron (REGN) and Sanofi's (SNY) Dupixent.
SNY Sanofi
$43.82

-0.57 (-1.28%)

09/10/18
MSCO
09/10/18
INITIATION
Target $72
MSCO
Overweight
MyoKardia initiated with an Overweight at Morgan Stanley
Morgan Stanley analyst Jeffrey Hung initiated MyoKardia (MYOK) at Overweight with a $72 price target, stating that the obstructive hypertrophic cardiomyopathy Phase 2 data for its lead program, mavacamten, were "robust" and the fact that the company is partnered with Sanofi (SNY) gives him incremental confidence. He expects a mavacamten launch in oHCM in early 2022 and peak U.S. sales for the drug of greater than $1.3B.
09/10/18
BOFA
09/10/18
UPGRADE
BOFA
Buy
Sanofi upgraded to Buy from Neutral at BofA/Merrill
BofA/Merrill analyst Graham Parry upgraded Sanofi to Buy from Neutral saying the company is approaching an inflection in growth from new products, mainly Dupixent, atopic, dermatitis, while diabetes becomes less of a headwind. Parry believes sales and earnings growth will accelerate to 7% from 4% in through 20-2023E and views valuation as undervaluing growth.
09/14/18
LSCM
09/14/18
NO CHANGE
Target $90
LSCM
Buy
Apple Watch more likely a positive for BioTelemetry, says Lake Street
After spending time with Joe Capper and Heather Getz, CEO and CFO of BioTelemetry (BEAT), Lake Street analyst Brooks O'Neil senses that Apple's (AAPL) Watch Series 4, which includes a built-in electrocardiogram, is more likely a positive for BioTelemetry "than a buzzer sounding a flat-line for the company's future." BioTelemetry remains the leading cardiac monitoring company and this is likely to continue for the foreseeable future, O'Neil tells investors in a research note. He points out the company has a partnership with Apple in cardiac monitoring and with Sanofi (SNY) and Alphabet (GOOG) in diabetes. The analyst's guesses that its partnership is one element giving BioTelemetry management comfort in evaluating the role Apple might play in the company's future. O'Neil reaffirms a Buy rating on the shares with a $90 price target.

TODAY'S FREE FLY STORIES

01:35
09/25/18
09/25
01:35
09/25/18
01:35
General news
Asian Market Wrap: »

Asian Market Wrap:…

FDS

FactSet

$231.53

-0.05 (-0.02%)

, JBL

Jabil

$30.08

0.22 (0.74%)

20:25
09/24/18
09/24
20:25
09/24/18
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

FDS

FactSet

$231.53

-0.05 (-0.02%)

JBL

Jabil

$30.08

0.22 (0.74%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 25

    Sep

  • 27

    Sep

  • 01

    Oct

  • 09

    Oct

  • 13

    Nov

LOXO

Loxo Oncology

$163.07

3.91 (2.46%)

20:16
09/24/18
09/24
20:16
09/24/18
20:16
Hot Stocks
Loxo Oncology granted orphan status for solid tumors treatment »

The FDA granted Loxo…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Nov

  • 27

    Nov

PTLA

Portola Pharmaceuticals

$27.16

-0.39 (-1.42%)

20:15
09/24/18
09/24
20:15
09/24/18
20:15
Hot Stocks
Portola granted orphan status for cerdulatinib »

The FDA granted Portola…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Dec

TNC

Tennant

$72.75

-1.15 (-1.56%)

20:01
09/24/18
09/24
20:01
09/24/18
20:01
Hot Stocks
Tennant to Acquire Gaomei Cleaning Equipment Company, terms not stated »

Tennant Company announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VNO

Vornado

$73.52

-1.58 (-2.10%)

19:20
09/24/18
09/24
19:20
09/24/18
19:20
Hot Stocks
Vornado now owns 100% interest in retail condo at Marriott Marquis Times Square »

Vornado Realty Trust…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

GOOG

Alphabet

$1,173.38

7.17 (0.61%)

, GOOGL

Alphabet Class A

$1,179.78

7.56 (0.64%)

19:08
09/24/18
09/24
19:08
09/24/18
19:08
Periodicals
Google CEO to meet with top Republican lawmakers Friday, WSJ says »

Google CEO Sundar Pichai…

GOOG

Alphabet

$1,173.38

7.17 (0.61%)

GOOGL

Alphabet Class A

$1,179.78

7.56 (0.64%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

  • 21

    Oct

  • 25

    Oct

  • 25

    Oct

  • 28

    Oct

  • 07

    Nov

  • 03

    Mar

ASNA

Ascena Retail

$4.02

-0.21 (-4.96%)

, BAS

Basic Energy

$9.44

0.18 (1.94%)

18:56
09/24/18
09/24
18:56
09/24/18
18:56
Hot Stocks
Fly Intel: After Hours Movers »

UP AFTER EARNINGS: Ascena…

ASNA

Ascena Retail

$4.02

-0.21 (-4.96%)

BAS

Basic Energy

$9.44

0.18 (1.94%)

KEG

Key Energy

$13.46

-0.18 (-1.32%)

PSTI

Pluristem

$1.31

(0.00%)

ARNA

Arena Pharmaceuticals

$42.80

-1.05 (-2.39%)

NOVN

Novan

$2.72

0.015 (0.56%)

SNDX

Syndax

$7.23

0.46 (6.79%)

DCPH

Deciphera

$39.80

0.78 (2.00%)

BJ

BJ's Wholesale

$28.47

-0.68 (-2.33%)

PETQ

PetIQ

$41.07

-0.55 (-1.32%)

CNP

CenterPoint Energy

$27.81

-0.23 (-0.82%)

CTL

CenturyLink

$22.90

-0.04 (-0.17%)

PBR

Petrobras

$11.40

-0.105 (-0.91%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Sep

  • 24

    Sep

  • 01

    Oct

  • 02

    Oct

  • 02

    Oct

  • 03

    Oct

  • 04

    Oct

  • 28

    Oct

  • 08

    Nov

  • 27

    Nov

  • 26

    Sep

  • 27

    Sep

  • 27

    Sep

PBR

Petrobras

$11.40

-0.105 (-0.91%)

18:54
09/24/18
09/24
18:54
09/24/18
18:54
Hot Stocks
Breaking Hot Stocks news story on Petrobras »

Petrobras reports August…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VRSN

VeriSign

$158.97

-0.79 (-0.49%)

18:39
09/24/18
09/24
18:39
09/24/18
18:39
Recommendations
VeriSign analyst commentary at JPMorgan »

VeriSign price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TI

Telecom Italia

$6.54

-0.1 (-1.51%)

18:35
09/24/18
09/24
18:35
09/24/18
18:35
Periodicals
Telecom Italia discussed Nextel bid at board meeting, Bloomberg says »

Telecom Italia's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INSG

Inseego

$4.01

-0.08 (-1.96%)

18:31
09/24/18
09/24
18:31
09/24/18
18:31
Hot Stocks
Inseego names John Weldon to head Enterprise SaaS Solutions division »

Inseego announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PCG

PG&E

$46.30

-0.48 (-1.03%)

18:31
09/24/18
09/24
18:31
09/24/18
18:31
Periodicals
PG&E says will invest $360M in electric car infrastructure, Bloomberg says »

PG&E senior manager…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 08

    Oct

  • 11

    Nov

KKR

KKR

$28.25

-0.01 (-0.04%)

18:21
09/24/18
09/24
18:21
09/24/18
18:21
Hot Stocks
KKR announces intra-quarter Q3 monetization activity »

KKR announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UNH

UnitedHealth

$267.35

0.6 (0.22%)

, EVHC

Envision Healthcare

$45.72

0.07 (0.15%)

18:17
09/24/18
09/24
18:17
09/24/18
18:17
Periodicals
UnitedHealth tells Hospitals about Envision ER contracts, Reuters says »

UnitedHealth (UNH) plans…

UNH

UnitedHealth

$267.35

0.6 (0.22%)

EVHC

Envision Healthcare

$45.72

0.07 (0.15%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 16

    Oct

AMZN

Amazon.com

$1,934.50

16.75 (0.87%)

, UBER

Uber

$0.00

(0.00%)

18:14
09/24/18
09/24
18:14
09/24/18
18:14
Periodicals
Amazon has made two approaches to buy Deliveroo, Telegraph reports »

Amazon has made two…

AMZN

Amazon.com

$1,934.50

16.75 (0.87%)

UBER

Uber

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

BK

BNY Mellon

$52.36

-0.9 (-1.69%)

17:48
09/24/18
09/24
17:48
09/24/18
17:48
Hot Stocks
BNY Mellon Investment Management to close EACM Advisors »

BNY Mellon Investment…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

EPZM

Epizyme

$10.23

-0.075 (-0.73%)

17:44
09/24/18
09/24
17:44
09/24/18
17:44
Initiation
Epizyme initiated at Leerink »

Epizyme initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Sep

  • 02

    Oct

NAVB

Navidea

$0.25

-0.0135 (-5.14%)

17:31
09/24/18
09/24
17:31
09/24/18
17:31
Hot Stocks
Breaking Hot Stocks news story on Navidea »

John K. Scott, Jr.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LYL

Dragon Victory

$1.46

(0.00%)

17:30
09/24/18
09/24
17:30
09/24/18
17:30
Hot Stocks
Breaking Hot Stocks news story on Dragon Victory »

White Knight Ltd reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RDS.A

Royal Dutch Shell

$68.18

0.89 (1.32%)

, RDS.B

Royal Dutch Shell

$70.25

0.67 (0.96%)

17:30
09/24/18
09/24
17:30
09/24/18
17:30
Periodicals
Shell CEO weighs $30B LNG export terminal in Canada, WSJ says »

Royal Dutch Shell CEO Ben…

RDS.A

Royal Dutch Shell

$68.18

0.89 (1.32%)

RDS.B

Royal Dutch Shell

$70.25

0.67 (0.96%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SEND

SendGrid

$35.40

-0.085 (-0.24%)

17:27
09/24/18
09/24
17:27
09/24/18
17:27
Initiation
SendGrid initiated at First Analysis »

SendGrid initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PGNX

Progenics

$6.44

0.03 (0.47%)

17:25
09/24/18
09/24
17:25
09/24/18
17:25
Hot Stocks
Breaking Hot Stocks news story on Progenics »

Armistice Capital reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Oct

  • 27

    Oct

VLY

Valley National

$11.76

-0.26 (-2.16%)

17:20
09/24/18
09/24
17:20
09/24/18
17:20
Hot Stocks
Valley National announces transfer of listing to Nasdaq »

Valley National Bancorp…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Oct

  • 01

    Nov

CPT

Camden Property

$93.35

-1.6 (-1.69%)

17:18
09/24/18
09/24
17:18
09/24/18
17:18
Hot Stocks
Camden Property completes acquisition of Florida apartment community »

Camden Property Trust…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.